Drug Search Results
More Filters [+]

Maprotiline

Alternative Names: maprotiline, ludiomil
Latest Update: 2022-08-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRA2A Antagonist,ADRA1A Antagonist,NRI Inhibitor,H1 Antagonist,mAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | France | Germany | Greece | Hungary | Indonesia | Ireland | Israel | Italy | Jordan | Lebanon | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Turkey | United Kingdom | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Maprotiline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title